Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 801–900 of 1,001
Christakos, S., & Pike, J. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00030-0 · Cited by 18
Cracking the Code: The Promise of Epigenetics
Dhanak, D. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300141h · Cited by 16
Ranking and compacting binding segments of protein families using aligned pattern clusters
Lee, E.-S., & Wong, A. K. C. (2013) · Proteome Science · doi:10.1186/1477-5956-11-s1-s8 · Cited by 16
Filipponi, P., & Baxendale, I. R. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201600222 · Cited by 16
Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma
Chen, H., Nikolić, A., Singhal, D., & Gallo, M. (2022) · Cancers · doi:10.3390/cancers14194942 · Cited by 20
“Over the past decade, a large arsenal of such drugs, often referred to as ‘epidrugs’ because of their targets, have been designed [102,103].”
BackgroundChromatin remodeling in tissue stem cell fate determination
Li, X., Zhu, G., & Zhao, B. T. (2024) · Cell Regeneration · doi:10.1186/s13619-024-00203-z · Cited by 17
“…link between the metabolic pathways accountable for the introduction of substrates and co-factors for chromatin-modifying enzymes and the gene expression mediated by chromatin-modifying enzymes needs to be well established to avoid dysregulation (Arrowsmith et al. 2012; Kaelin and McKnight 2013).”
BackgroundKumari, K., Adhya, A. K., Rath, A. K., Reddy, P. B., & Mishra, S. K. (2018) · BMC Cancer · doi:10.1186/s12885-018-4586-0 · Cited by 15
Ala, M., Jafari, R. M., Nematian, H., Ganjedanesh, M. R., & Dehpour, A. R. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.09.036 · Cited by 16
Bitzer, M., & Malek, N. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00042-9 · Cited by 15
Hoekstra, M., & Biggar, K. K. (2021) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114429 · Cited by 16
Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma
Hanly, A. M., Gibson, F. T., Nocco, S. E., Rogers, S., Wu, M., & Alani, R. M. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100090 · Cited by 19
“increased gene transcription (Arrowsmith et al., 2012), which may be associated with cancer (Portela and Esteller, 2010) (Figure 1f).”
BackgroundInfluentialImmune chromatin reader SP140 regulates microbiota and risk for inflammatory bowel disease
Fraschilla, I. R., Amatullah, H., Rahman, R., & Jeffrey, K. L. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.08.018 · Cited by 21
Therapeutic vulnerabilities of cancer stem cells and effects of natural products
Reisenauer, K. N., Aroujo, J., Tao, Y., Ranganathan, S., Romo, D., & Taube, J. H. (2023) · Natural Product Reports · doi:10.1039/d3np00002h · Cited by 15
Cortopassi, W. A., Kumar., K., V, Duarte, F., Pimentel, A. S., & Paton, R. S. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.04.011 · Cited by 18
“Our focus is on mechanistic work rather than non-covalent inhibition: we refer readers to recent excellent reviews concerning the development of epigenetic inhibitors [15-20] and recent works regarding accurate binding free energy predictions.”
BackgroundTudor Domains as Methyl-Lysine and Methyl-Arginine Readers
Botuyan, M. V., & Mer, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802389-1.00008-3 · Cited by 18
The chromatin-associated Sin3B protein is required for hematopoietic stem cell functions in mice
Cantor, D. J., & David, G. (2016) · Blood · doi:10.1182/blood-2016-06-721746 · Cited by 19
Development of New Positron Emission Tomography Radiotracer for BET Imaging
Wang, C., Schroeder, F. A., & Hooker, J. M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00288 · Cited by 15
Epigenetic modulation as a therapy in systemic sclerosis
O’Reilly, S. (2018) · Rheumatology · doi:10.1093/rheumatology/key071 · Cited by 15
Chen, W., Zhang, H., Chen, Z., Jiang, H., Liao, L., Fan, S., Xing, J., Xie, Y., Chen, S., Ding, H., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0093-z · Cited by 15
Noblejas‐López, M. D. M., Morcillo-García, S., Nieto‐Jiménez, C., Nuncia‐Cantarero, M., Győrffy, B., Galán‐Moya, E. M., Pandiella, A., & Ocaña, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207776 · Cited by 20
“Regulation of transcription is a key process in cellular homeostasis [1, 2].”
BackgroundInfluentialHu, J., Liu, Y., & Zhang, C. (2020) · Nanoscale · doi:10.1039/c9nr10376g · Cited by 15
Luan, Y., Ngo, L., Han, Z. H., Wang, X., Qu, M., & Zheng, Y. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801080-8.00014-4 · Cited by 15
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 15
Li, M., Yu, H., Li, Y. M., Li, X., Huang, S., Liu, X., Weng, G., Xu, L., Hou, T., Guo, D., et al. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115716 · Cited by 14
Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery
Chan, A., Han, L., Delaney, C. D., Wang, X., Mukhaleva, E., Li, M., Yang, L., Pokharel, S. P., Mattson, N. M., Garcia, M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk3127 · Cited by 16
“Thus, targeting the indispensable epigenetic circuitries represents a field of opportunity for more effective therapies in hematopoietic disorders ( 6 ).”
BackgroundVos, N., Haghshenas, S., van der Laan, L., Russel, P. K. M., Rooney, K., Levy, M. A., Relator, R., Kerkhof, J., McConkey, H., Maas, S. M., et al. (2024) · Human Genetics · doi:10.1007/s00439-024-02679-w · Cited by 16
“…lysine on histone and non-histone proteins (‘epi-genetic reading’) and are involved in various processes (histone modification, chromatin remodeling and transcriptional regulation) that have an effect on gene expression (Podcheko et al. 2007; Arrowsmith et al. 2012; Filippakopoulos et al. 2012).”
BackgroundSingle-cell EpiChem jointly measures drug–chromatin binding and multimodal epigenome
Dong, C. F., Meng, X., Zhang, T., Guo, Z., Liu, Y., Wu, P., Chen, S., Zhou, F., Ma, Y., Xiong, H., et al. (2024) · Nature Methods · doi:10.1038/s41592-024-02360-0 · Cited by 17
“5 and 7).”
Lyu, K., Ren, Y., Mou, J., Yang, Y., Pan, Y., Zhang, H., Li, Y., Cao, D., Chen, L., Chen, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01933 · Cited by 14
Epigenetic Mechanisms of Resveratrol and Its Analogs in Cancer Prevention and Treatment
Kumar, A., & Levenson, A. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00008-1 · Cited by 18
Epigenetic Programming of Adipose Tissue in the Progeny of Obese Dams
Lecoutre, S., Kwok, K. H. M., Petrus, P., Lambert, M., & Breton, C. (2019) · Current Genomics · doi:10.2174/1389202920666191118092852 · Cited by 16
Chen, C., Lu, T., Chen, P., Li, Z., Yang, Y., Fan, S., Zhang, Y., Chen, K., Fu, W., Wang, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115023 · Cited by 14
Guo, S., Jia, T., Xu, X., Yang, F., Xiao, S.-H., Hou, Z., Xu, H., Ma, S., Liu, X., Luo, C., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115093 · Cited by 14
Helgudóttir, S. S., Mørkholt, A. S., Lichota, J., Bruun-Nyzell, P., Andersen, M. C., Kristensen, N. M. J., Johansen, A. K., Zinn, M. R., Jensdóttir, H. M., & Nieland, J. D. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.387965 · Cited by 17
“…factors exert a regulatory influence on gene expression, operating in conjunction with transcription factors that govern the transcriptome, in order to regulate how and when genes are expressed depending on the changing environment (Qureshi and Mehler, 2011; Arrowsmith et al., 2012; Szyf, 2015).”
BackgroundEpigenetics in Schistosomes: What We Know and What We Need Know
Liu, W. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00149 · Cited by 12
“Histone methylation is completed by S-adenosylmethioninedependent methyltransferase and occurs on lysine or arginine residues in histone tails (Beaver and Waters, 2016).”
BackgroundDevelopment of Chemical Tools to Monitor and Control Isoaspartyl Peptide Methyltransferase Activity
Kimura, Y., Komatsu, T., Yanagi, K., Hanaoka, K., Ueno, T., Terai, T., Kojima, H., Okabe, T., Nagano, T., & Urano, Y. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608677 · Cited by 15
Tumor-augmenting effects of gestational arsenic exposure on F1 and F2 in mice
Nohara, K., Suzuki, T., Okamura, K., Matsushita, J., & Takumi, S. (2017) · Genes and Environment · doi:10.1186/s41021-016-0069-1 · Cited by 16
Epigenetic interplay at the β-globin locus
Lee, W. S., McColl, B., Maksimovic, J., & Vadolas, J. (2017) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.01.014 · Cited by 15
“The addition of an acetyl (-COCH3) group to the histone lysine side chain counteracts the positive charge of the protein, resulting in reduced charge-dependent interactions with the DNA backbone, and a more open chromatin structure, accessible to the transcriptional apparatus [61].”
BackgroundInfluentialEpigenetic Mechanisms of Alcohol Neuroadaptation: Insights from Drosophila
Ramirez-Roman, M. E., Billini, C. E., & Ghezzi, A. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518779809 · Cited by 14
Dewaker, V., Srivastava, P. N., Verma, S. K., & Prabhakar, Y. S. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1598497 · Cited by 14
“Based on the similarity between yeast’s Zn2þ dependent HDAC sequences and that of the human, the latter ones are categorized as Class I (HDAC-1, -2, -3, and -8), Class IIa (HDAC-4, -5, -7, and -9), Class IIb (HDAC6 and -10), and Class IV (HDAC-11) (Arrowsmith et al., 2012).”
BackgroundItoh, Y. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00741 · Cited by 15
Cacabelos, R., & Torrellas, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00032-6 · Cited by 18
de Souza, L. Â., Bastos, M. S. E., Agripino, J. D. M., Onofre, T. S., Calla, L. F. A., Heimburg, T., Ghazy, E., Bayer, T., da Silva, V. H. F., Ribeiro, P. D., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114191 · Cited by 17
Histone Variant H3.3 Mutations in Defining the Chromatin Function in Mammals
Trovato, M., Patil, V., Gehre, M., & Noh, K. (2020) · Cells · doi:10.3390/cells9122716 · Cited by 16
“, EZH2 inhibitors, bromodomain antagonists, histone deacetylase inhibitors) and the possibility to modulate the activity of epigenetic factors for therapeutic purposes, have advanced the use of small-molecules as an alternative and complementary approach to the study of histone-modifying enzymes and chromatin readers…”
BackgroundHistone Modifying Enzymes in Gynaecological Cancers
Ramarao-Milne, P., Kondrashova, O., Barry, S. C., Hooper, J. D., Lee, J. S., & Waddell, N. (2021) · Cancers · doi:10.3390/cancers13040816 · Cited by 15
“There is a great interest in epigenetic drug targets in cancer [3,4], an area actively pursued in gynaecological cancers.”
BackgroundEpigenetic Drug Discovery for Alzheimer’s Disease
Cacabelos, R., & Teijido, Ó. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811060-7.00022-x · Cited by 18
Discovery of a PCAF Bromodomain Chemical Probe
Moustakim, M., Clark, P. G. K., Trulli, L., de Arriba, A. L. F., Ehebauer, M. T., Chaikuad, A., Murphy, E. J., Méndez, J., Daniels, D. L., Hou, C.-F. D., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201610816 · Cited by 14
Epigenetic Pathways of Oncogenic Viruses: Therapeutic Promises
El‐Araby, A. M., Fouad, A. A., Hanbal, A. M., Abdelwahab, S. M. M., Qassem, O. M., & El‐Araby, M. E. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201500375 · Cited by 15
Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303.v1 · Cited by 16
Personalized Pharmacoepigenomics
Peedicayil, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420135-4.00012-7 · Cited by 13
Hoekstra, M., Ridgeway, N. H., & Biggar, K. K. (2022) · The Journal of Biochemistry · doi:10.1093/jb/mvac081 · Cited by 13
Wakim, J. G., & Spakowitz, A. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317911121 · Cited by 13
Wang, Z., Abudurexiti, M., Zhu, W., Li, T., Xu, H., Wan, F., & Ye, D. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00904-x · Cited by 18
Interaction Between DNA/histone Methyltransferases and their Inhibitors
Hu, J., Chen, S., Kong, X., Zhu, K., Cheng, S., Zheng, M., Jiang, H., & Luo, C. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106114538 · Cited by 13
Li, S., Gu, X., Hao, Q., Fan, H. X., Li, L., Zhou, S., Zhao, K., Chan, H. M., & Wang, Y. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.08.029 · Cited by 13
ChEpiMod: a knowledgebase for chemical modulators of epigenome reader domains
Meslamani, J. E., Smith, S. G., Sánchez, R., & Zhou, M. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu052 · Cited by 13
Rajajeyabalachandran, G., Kumar, S., Murugesan, T., Shanthi, E., Padmavathy, R., Jegatheesan, S. K., Mullangi, R., & Rajagopal, S. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272580 · Cited by 13
Unveiling the Biochemistry of the Epigenetic Regulator SMYD3
Fabini, E., Talibov, V., Mihalič, F., Naldi, M., Bartolini, M., Bertucci, C., Río, A. D., & Danielson, U. H. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00420 · Cited by 13
Pu, D.-B., Guo, S., Ni, D., Lin, J., Gao, J., Li, X., Zhang, R., Li, X., Luo, C., Chen, S., et al. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00775 · Cited by 13
Efficient cell chatting between embryo and uterus ensures embryo implantation
Deng, W., & Wang, H. (2022) · Biology of Reproduction · doi:10.1093/biolre/ioac135 · Cited by 13
“As an important sensor of external environment, epigenetic medication also contributes to inherent diversity by programmed DNA packaging [22].”
BackgroundHart, P. ‘., Thomas, D., Ommeren, R. V., Lakowski, T. M., Frankel, A., & Martin, N. I. (2012) · MedChemComm · doi:10.1039/c2md20161e · Cited by 13
Liu, H., Li, Z., & Li, L. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.04.005 · Cited by 14
Elsner, V. R., de Menezes, M., Nicola, F., da Silva, I. V., Vizuete, A. F. K., Xavier, L., Gonçalves, C.-A. S., Netto, C. A., & Mestriner, R. G. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.239443 · Cited by 13
“In addition, other epigenetic mechanisms, such as DNA methylation, acetylation of other histones, or lysine-specific acetylation in histone tails (Kurdistani et al., 2004; Saha and Pahan, 2006; Pelzel et al., 2010; Arrowsmith et al., 2012; Maleszkam, 2016), might influence cellular mechanisms in remodeling neural tiss…”
Gut Injury and the Microbiome in Neonates
Pammi, M., Hollister, E. B., & Neu, J. (2020) · Clinics in Perinatology · doi:10.1016/j.clp.2020.02.010 · Cited by 13
Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension
Gerthoffer, W. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239222 · Cited by 13
“Bromodomain-containing proteins bind acetylated lysine residues on histones and function as transcriptional coactivators in the histone code “reader” machinery [45,46].”
BackgroundA Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma
Emran, A. A., Tseng, H., Gunatilake, D., Cook, S. J., Ahmed, F., Wang, S., Hersey, P., Gallagher, S. J., & Tiffen, J. C. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.12.038 · Cited by 13
“Particular interest has focused on the development of inhibitors against a highly conserved class of reader proteins, referred to as BET proteins, which are emerging as promising drug targets (Alqahtani et al., 2019; Arrowsmith et al., 2012; Ernst and Kellis, 2012).”
BackgroundIntrinsic Dynamics of the Binding Rail and Its Allosteric Effect in the Class I Histone Deacetylases
Zhou, J., Huang, Y., Cheng, C., Wang, K., & Wu, R. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00251 · Cited by 13
Epigenetic drugs for A lzheimer's disease: hopes and challenges
Caraci, F., Leggio, G. M., Drago, F., & Salomone, S. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04443.x · Cited by 14
Toward the Prediction of Binding Events in Very Flexible, Allosteric, Multidomain Proteins
Basciu, A., Athar, M., Kurt, H., Neville, C., Malloci, G., Muredda, F. C., Bosin, A., Ruggerone, P., Bonvin, A. M. J. J., & Vargiu, A. V. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01810 · Cited by 12
“56,57 58 − 60 While cofactors such as Mg 2+ are essential for the catalysis, 61,62 substrate binding and related conformational changes are believed to be largely independent of their presence.”
Benhima (1962) · Présence Africaine · doi:10.3917/presa.042.0147 · Cited by 13
Epigenetic therapies - a new direction in clinical medicine
Stein, R. A. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12436 · Cited by 13
Ashenden, S. K., Kogej, T., Engkvist, O., & Bender, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00295 · Cited by 12
PeSA: A software tool for peptide specificity analysis
Topcu, E., & Biggar, K. K. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107145 · Cited by 12
Wang, Y., Zhang, L., Zhou, X., Yang, S.-J., Ahmad, M. J., Ding, Z., Duan, Z., Chen, Y., Liu, M., Zhang, S.-X., et al. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110192 · Cited by 12
MetaHMEI: meta-learning for prediction of few-shot histone modifying enzyme inhibitors
Lü, Q., Zhang, R., Zhou, H., Ni, D., Xiao, W., & Li, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad115 · Cited by 12
Combined low levels of H4K16ac and H4K20me3 predicts poor prognosis in breast cancer
Wang, B., Zhou, M., Gan, X.-L., Ren, Y.-X., Yang, Y., Weng, Z., Zhang, X., Guan, J., Tang, L.-Y., & Ren, Z. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02378-y · Cited by 13
PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
Kordala, A. J., Stoodley, J., Ahlskog, N., Hanifi, M., Garcia-Guerra, A., Bhomra, A., Lim, W. F., Murray, L. M., Talbot, K., Hammond, S. M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317683 · Cited by 14
“…methyltransferases (PRMTs), histone lysine methyltransferases (KMTs) and demethy-lases (KDMs), and bromodomain-containing proteins (BRD) have emerged as attractive druggable targets using small molecules, due to the dynamic nature of disease-associated epigenetic states (Arrowsmith et al , 2012).”
BackgroundParseghian, M. H. (2013) · Biochemistry and Cell Biology · doi:10.1139/bcb-2013-0059 · Cited by 12
“Chromatin research is now entering the clinic with scientists evaluating drug targets on the proteins that mediate epigenetic signals (Arrowsmith et al. 2012).”
BackgroundMaegley, K. A., Krivacic, C. T., Bingham, P., Liu, W., & Brooun, A. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.640 · Cited by 12
“7,8 While PMTs have proven to be druggable, 7,9–12 identification of bone-fide leads with good ligand efficiency and physico-chemical properties has proven challenging for many enzymes in this class.”
Evolution of an Epigenetic Gene Ensemble within the Genus Anopheles
Jenkins, A. M., & Muskavitch, M. A. T. (2015) · Genome Biology and Evolution · doi:10.1093/gbe/evv041 · Cited by 13
“…to orthologs in model or highly studied organisms (e.g., Homo sapiens), few comparisons of epigenetic gene ensembles have been conducted among dipteran species, including species within the malaria vector genus Anopheles (Arrowsmith et al. 2012; Talbert et al. 2012; Gregoretti et al. 2004).”
BackgroundMethodInfluentialWang, L., Kofler, M., Brosch, G., Melesina, J., Sippl, W., Martínez, E. D., & Easmon, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134556 · Cited by 14
“In disease, this regulation of the transcriptional process can be altered as a consequence of changes in the expression or function of epigenetic enzymes [1,2].”
BackgroundIt’s Time for An Epigenomics Roadmap of Heart Failure
Papait, R., Corrado, N., Rusconi, F., Serio, S., & Latronico, M. V. G. (2015) · Current Genomics · doi:10.2174/1389202916666150505183624 · Cited by 13
“Although this muddles the understanding of their function, it opens up the possibility of designing more-specific epigenetic therapies than those based on the use of HDAC/DNMT inhibitors [39].”
MethodMinireview: Therapeutic Implications of Epigenetic Signaling in Breast Cancer
Oh, T. G., Wang, S.-C., & Muscat, G. E. O. (2016) · Endocrinology · doi:10.1210/en.2016-1716 · Cited by 14
“Epigenetic modifications are driven by enzymes including the DNA methyltransferases (DNMTs), lysine methyltransferases (KMTs), lysine demethylases (KDMs), protein arginine methyltransferases (PRMTs), histone lysine acetyltransferases (HATs), and histone lysine deacetylases (HDACs), which impact on transcription and ca…”
Exploring Cocrystallized Aromatic Cage Binders to Target Histone Methylation Reader Proteins
Li, J., Moumbock, A. F. A., & Günther, S. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00765 · Cited by 12
Epigenetics: A New Link Toward Understanding Human Disease and Drug Response
Cressman, A. M., & Piquette‐Miller, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.179 · Cited by 12
Jiao, P., Jin, P., Li, C., Cui, L., Dong, L., Pan, B., Song, W., Ma, L., Dong, J., Song, L., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.073 · Cited by 13
Discovery of Potent Peptidomimetic Antagonists for Heterochromatin Protein 1 Family Proteins
Lamb, K. N., Dishman, S. N., Waybright, J. M., Engelberg, I. A., Rectenwald, J. M., Norris-Drouin, J. L., Cholensky, S. H., Pearce, K. H., James, L. I., & Frye, S. V. (2021) · ACS Omega · doi:10.1021/acsomega.1c05381 · Cited by 13
The epigenetic regulation of the germinal center response
Wu, S., Yin, Y., & Wang, X. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194828 · Cited by 12
Recent advances in developing degraders & inhibitors of lysine methyltransferases
Velez, J., Kanıskan, H. Ü., & Jin, J. J. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102356 · Cited by 13
Opportunities and Difficulties in the Repurposing of HDAC Inhibitors as Antiparasitic Agents
Mohapatra, T. K., Nayak, R. R., Ganeshpurkar, A., Tiwari, P. K., & Kumar, D. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3010006 · Cited by 11
Structural diversity of the epigenetics pocketome
Cabayé, A., Nguyen, K. T., Liu, L., Pande, V., & Schapira, M. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24830 · Cited by 11
Self-citationLin, Z., Bishop, K. S., Sutherland, H. S., Marlow, G., Murray, P., Denny, W. A., & Ferguson, L. R. (2016) · Molecular BioSystems · doi:10.1039/c5mb00554j · Cited by 12
Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron
Kavianpour, P., Gemmell, M., Kahlert, J. U., & Rendina, L. M. (2020) · ChemBioChem · doi:10.1002/cbic.202000131 · Cited by 11
Hallaj, T., Amjadi, M., Qiu, X., Susumu, K., Medintz, I. L., & Hildebrandt, N. (2020) · Nanoscale · doi:10.1039/d0nr03383a · Cited by 12
FAT‐Free p300 Is Good for Scar‐Free Tissue Repair
Ghosh, A. K. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24820 · Cited by 11
“In the late 1990s, several studies recognized the significance of epigenetics, a method of alteration of gene expression without affecting DNA sequences, in initiation and progression of different human diseases [Arrowsmith et al., 2012], and became a hot topic of biomedical research.”
BackgroundYoshida, W., Kezuka, A., Abe, K., Wakeda, H., Nakabayashi, K., Hata, K., & Ikebukuro, K. (2013) · Analytical Chemistry · doi:10.1021/ac401036k · Cited by 11
Safavi, M., Sabourian, R., & Abdollahi, M. R. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1217196 · Cited by 12
“The routine use of diagnostic genetic testing in cancer patients to inform treatment decisions is limited [99,100].”
BackgroundBromodomain Factor 5 as a Target for Antileishmanial Drug Discovery
(2023) · doi:10.1021/acsinfecdis.3c00431 · Cited by 10
The Epigenetics Orchestra of Notch Signaling: A Symphony for Cancer Therapy
Paniri, A., Hosseini, M. M., Amjadi‐Moheb, F., Tabaripour, R., Soleimani, E., Langroudi, M. P., Zafari, P., & Akhavan‐Niaki, H. (2023) · Epigenomics · doi:10.2217/epi-2023-0270 · Cited by 11
Kumari, S., Gupta, S., Sukhija, R., Gurjar, S., Dubey, S. K., & Taliyan, R. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177123 · Cited by 10
Wei, K., Peng, C., Ou, Y., Wang, P., Zhan, C., Wei, H., Na, J., & Zhang, Z. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040263 · Cited by 14
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.